Publications by authors named "Marc Chevrier"

Claim this Profile
N
New generation of Abbott enzyme assays: imprecision, methods comparison, and impact on patients' results.
Marc Chévrier, Audrey Frugier, Sylvie Colognac, Denis Monneret

Clin Chem Lab Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-linearity in lipase assays: A multicentric comparison on different analysers.
Denis Monneret, Amélie Moreau, Carole Chirica, Dorra Guergour, Caroline Richet

Clin Biochem· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
Ronald F van Vollenhoven, Bevra H Hahn, George C Tsokos, Peter Lipsky, Robert M Gordon, Marc Chevrier

J Rheumatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stability of lactate in venous blood gas and sodium fluoride-potassium oxalate plasma: a 6-year retrospective database analysis.
Nelu Nadejde, Yassir Lemseffer, Laurent Desmurs, Sabine Zaepfel, Flora Kaczorowski

Clin Chem Lab Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Myocardial injury in coronavirus disease 19 (Covid-19): main pathophysiological mechanisms and clinical utility of cardiac biomarkers].
Said Kamel, Alexandre Raynor, Samuel Zozor, Geneviève Lacape, Valéry Brunel

Ann Biol Clin (Paris)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
Loqmane Seridi, Matteo Cesaroni, Ashley Orillion, Jessica Schreiter, Marc Chevrier

Lupus· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Matteo Cesaroni, Loqmane Seridi, Matthew J Loza, Jessica Schreiter, Kristen Sweet, Marc Chevrier

Arthritis Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Zhenling Yao, Laura Loggia, Damien Fink, Marc Chevrier, Stanley Marciniak

Clin Drug Investig· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Roberta Turiello, Mariaelena Capone, Diana Giannarelli, Elva Morretta, Maria Chiara Monti, Marc Chevrier

J Immunother Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial.
Jarrat Jordan, Jacqueline Benson, Walter Winn Chatham, Richard Alan Furie, William Stohl, Marc Chevrier

Lancet Rheumatol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
Ronald F van Vollenhoven, Bevra H Hahn, George C Tsokos, Peter Lipsky, Kaiyin Fei, Marc Chevrier

Arthritis Rheumatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
Héloïse M Delagreverie, Claire Bauduin, Nathalie De Castro, Beatriz Grinsztejn, Marc Chevrier

Open Forum Infect Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.
Bethany D Harris, Jessica Schreiter, Marc Chevrier, Jarrat L Jordan, Mark R Walter

J Biol Chem· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
Ronald F van Vollenhoven, Bevra H Hahn, George C Tsokos, Carrie L Wagner, Peter Lipsky, Marc Chevrier

Lancet· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.
Michael A Loesche, Kamyar Farahi, Kimberly Capone, Steven Fakharzadeh, Andrew Blauvelt, Marc Chevrier

J Invest Dermatol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
Joseph E Huffstutter, Shelly Kafka, Lawrence H Brent, Marco Matucci-Cerinic, Kezhen L Tang, Marc Chevrier

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group.
Mathurin Fumery, Philippe Seksik, Claire Auzolle, Nicolas Munoz-Bongrand, Jean-Marc Gornet, Marc Chevrier

Am J Gastroenterol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Miguel Regueiro, Brian G Feagan, Bin Zou, Jewel Johanns, Marion A Blank, Marc Chevrier

Gastroenterology· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Robert E Kalb, David F Fiorentino, Mark G Lebwohl, John Toole, Yves Poulin, Marc Chevrier

JAMA Dermatol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kim Papp, Alice B Gottlieb, Luigi Naldi, David Pariser, Vincent Ho, Marc Chevrier

J Drugs Dermatol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Kim Papp, Alice B Gottlieb, Luigi Naldi, David Pariser, Vincent Ho, Marc Chevrier

J Am Acad Dermatol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Alice B Gottlieb, Robert E Kalb, Richard G Langley, Gerald G Krueger, Elke M G J de Jong, Marc Chevrier

J Drugs Dermatol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Robert E Kalb, Andrew Blauvelt, Howard L Sofen, Marc Chevrier, David Amato

J Drugs Dermatol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
Alice B Gottlieb, Robert E Kalb, Andrew Blauvelt, Michael P Heffernan, Howard L Sofen, Marc Chevrier

J Am Acad Dermatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Kim A Papp, Bruce Strober, Matthias Augustin, Steve Calabro, Anil Londhe, Marc Chevrier

J Drugs Dermatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis